AUSTIN, Texas--(BUSINESS WIRE)--AustinPx, developers of the next-generation amorphous dispersion platform, KinetiSol™ Technology, and a contract development and manufacturing organization (CDMO), is proud to announce that it has been named the winner of the Accelerating Innovation Award at the 2024 CPHI Pharma Awards for its groundbreaking KinetiSol Technology. The award recognizes outstanding achievement in solutions that address critical challenges within the pharmaceutical industry.
KinetiSol’s fusion-based, solvent-free process has revolutionized the approach to enhancing the bioavailability of poorly soluble drugs. Designed to meet the growing demand for more sustainable drug manufacturing processes, KinetiSol has successfully combined superior bioavailability enhancement performance with environmental responsibility and optimized manufacturability. AustinPx’s advanced amorphous dispersion technology eliminates the need for organic solvents, dramatically reducing environmental impact and operational costs while delivering enhanced bioavailability for drug candidates with high melting points and poor solvent solubility.
"The Accelerating Innovation award is a testament to the hard work and dedication of the entire team at AustinPx,” said Elizabeth Hickman, chief business officer and incoming CEO of AustinPx. “We are passionate about advancing solutions that benefit our clients and reduce the environmental impact of pharmaceutical manufacturing. KinetiSol is designed to improve bioavailability and sustainability, allowing us to contribute to a healthier planet while delivering innovative drug solutions."
KinetiSol is uniquely positioned to address the growing trend of poorly soluble drugs in the pharmaceutical pipeline, where current methods often fall short. Beyond eliminating harmful solvents, the technology offers faster processing times, streamlined scale-up, and lower developmental costs, making it a preferred solution for even the most complex molecules. With its impressive track record, KinetiSol has been applied to over 40 molecules in the last 18 months and successfully advanced multiple programs to clinical trial testing.
"This recognition strengthens our resolve to push for even greater advances in sustainable technology," added Hickman. "We look forward to continuing our innovation journey and helping shape the future of pharmaceutical development."
Hickman accepted the award at the CPHI Pharma Awards ceremony in Milan, Italy, on October 8. The CPHI Pharma Awards, known for highlighting the industry’s most innovative technologies and companies, honor those who push the boundaries of pharmaceutical innovation.
AustinPx is proud to join the ranks of past winners and continues to lead the charge in developing transformative solutions for drug formulation and delivery. For more information about KinetiSol Technology and AustinPx’s industry-leading solutions, visit www.austinpx.com.
About AustinPx
AustinPx, Pharmaceutics and Manufacturing, is a contract development and manufacturing organization (CDMO) providing analytical and formulation development services and cGMP manufacturing for small molecule drugs. AustinPx specializes in phase-appropriate development strategies, speed to clinic and market strategies, and bioavailability enhancement of poorly soluble molecules - including our next-generation amorphous dispersion platform, KinetiSol™ Technology. For more information, visit www.AustinPx.com.
